美国三个安全网医疗系统中慢性乙型肝炎患者的丁型肝炎病毒检测与患病率
本研究回顾性评估2010至2022年美国3个安全网医疗系统13218例慢性乙型肝炎患者,抗-HDV检测率仅6.1%,符合美国肝病研究学会检测标准者中仅4.9%接受检测;受检者中15.7%抗-HDV阳性,仅2例(1.6%)接受随访HDV RNA检测。
要点
- 慢性乙型肝炎患者中抗-HDV检测率仅6.1%,符合美国肝病研究学会检测标准者中也仅4.9%接受检测。
- 受检者中15.7%抗-HDV阳性,符合美国肝病研究学会检测标准者中阳性率为22.9%。
- 仅2例(1.6%)受检者接受随访HDV RNA检测,作者呼吁加强宣传、教育和倡导以提高检测率。
核心结论
- 在族裔多样、多中心的安全网慢性乙型肝炎队列中,HDV检测率低,即使在高风险因素患者中也是如此;受检者中15.7%抗-HDV阳性,仅2例接受随访RNA检测,作者认为需要加强宣传、教育和倡导以提高HDV检测率。
研究设计与样本
- 回顾性评估2010至2022年美国3个安全网医疗系统共13218例慢性乙型肝炎患者,其中男性54.2%、非白人少数族裔57.9%、人类免疫缺陷病毒12.5%、丙型肝炎病毒23.0%。
- 采用调整多因素logistic回归模型评估HDV检测的预测因素和抗-HDV阳性的预测因素。
主要发现
- 总体抗-HDV检测率为6.1%,符合美国肝病研究学会HDV检测标准者中检测率为4.9%。
- 男性较女性检测比值更高(OR 1.49;95%CI 1.27-1.75),亚洲人较白人(OR 2.18;95%CI 1.74-2.72)、黑人或非裔美国人较白人(OR 1.29;95%CI 1.07-1.56)检测比值更高,享有Medicare或Medicaid者检测比值也更高。
- 受检的慢性乙型肝炎患者中15.7%抗-HDV阳性,符合美国肝病研究学会HDV检测标准者中阳性率为22.9%;仅2例(1.6%)接受随访HDV RNA检测。
- 基线肝硬化患者抗-HDV阳性比例高于无肝硬化者(47.4% vs 13.3%;P < .001),享有Medicare或Medicaid者较商业保险者抗-HDV阳性比例更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite a high prevalence of risk factors associated with hepatitis delta virus (HDV) infection among safety-net populations, data evaluating HDV testing and prevalence are limited. We aim to evaluate HDV testing practices and HDV prevalence among an ethnically diverse, multi-center cohort of safety-net patients with chronic hepatitis B (CHB). METHODS: We retrospectively evaluated 13,218 patients with CHB (54.2% male, 57.9% non-White minorities, 12.5% human immunodeficiency virus, and 23.0% hepatitis C virus) across 3 United States safety-net health systems from 2010 to 2022 to evaluate proportion tested for HDV and proportion positive among those tested. Adjusted multivariate logistic regression models evaluated for predictors of HDV testing and predictors of anti-HDV positive. RESULTS: Anti-HDV testing was performed in 6.1% overall and in 4.9% that met American Association for the Study of Liver Diseases criteria for HDV testing. Greater odds of testing were observed in men vs women (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.27-1.75), Asian individuals vs White individuals (OR, 2.18; 95% CI, 1.74-2.72), Black/African American individuals vs White individuals (OR, 1.29; 95% CI, 1.07-1.56), and patients with Medicare or Medicaid. Among patients with CHB tested for HDV, 15.7% were positive (22.9% among those meeting American Association for the Study of Liver Diseases HDV testing criteria). Only 2 patients (1.6%) had follow-up HDV RNA testing. Greater proportion of anti-HDV positive was observed in patients with baseline cirrhosis (47.4% vs 13.3%; P < .001), and patients with Medicare or Medicaid vs those with commercial insurance. CONCLUSIONS: Among an ethnically diverse, multi-center safety-net cohort of patients with CHB, low rates of HDV testing were observed, even among those with high-risk HDV risk factors. Among those tested, 15.7% were positive, only 2 had follow up RNA testing. This highlights the need for greater awareness, education, and advocacy to improve HDV testing rates.
引用
- Wong RJ, Jain MK, Niu B, et al. Hepatitis Delta Virus Testing and Prevalence Among Chronic Hepatitis B Patients Across Three U.S. Safety-net Health Systems. Clin Gastroenterol Hepatol. 2024. PMID: 39461463. doi:10.1016/j.cgh.2024.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。